Not Tagged
Not Tagged
['biomarker']
in the absence of subgroup differences, the discussant says it s unclear who can be delayed to start cdk4/6 at 2l v 1l. that s not right. in the absence of biomarkers, all patients can be delayed. you rather need a biomarker to prove some patients need to get it 1l. #asco23 
Personal account. Med Onc. Associate Prof. @queensoncology @QueensuPHS. #cancerpolicy #cancergroundshot. Pubs: https://t.co/FTRPKNykq3 Talks- https://t.co/anav3AIZjO